Skip to main content
PBF logo

PBF — Investor Relations & Filings

Ticker · 1760 ISIN · TW0001760007 LEI · 54930078VUU2LBPR2729 TW Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2024-09-09 Regulatory Filings
Country TW Taiwan
Listing TW 1760

About PBF

http://www.pbf.com.tw

Panion & BF Biotech Inc. is a biotechnology company focused on pharmaceutical research, development, and manufacturing. Founded in 1976, the firm operates across several core sectors, including new drug innovation, medical aesthetics, and nutritional supplements. It is recognized for its "Total Aging Management" strategy, which addresses the health needs of an aging population through a diverse product portfolio. Key offerings include treatments for chronic kidney disease, specifically phosphate binders, as well as dermatological drugs, hair care solutions, and rapid diagnostic technologies. The company integrates clinical-grade pharmaceutical standards into its consumer health and aesthetic products, serving markets in chronic disease care and preventative wellness.

Recent filings

Filing Released Lang Actions
113年8月營業收入
Regulatory Filings Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 寶齡富錦, presented in a tabular format with explanations about accounting standards and reporting practices. It contains financial data for August 2024 (民國113年08月) and compares it to the previous year. The document is short (775 characters) and appears to be a periodic financial summary rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It also does not fit other categories like Earnings Release or Investor Presentation. Given the nature of the data and the length, this is best classified as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements and financial summaries that do not fit other specific categories.
2024-09-09 Chinese
113年08月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, managers, and their related parties. It lists share types, quantities held at different times, increases and decreases in holdings, and other related information. There is no indication of financial statements, earnings data, management discussion, or other report content. Instead, it is a disclosure of insider shareholdings and transactions. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is sufficient and the content is consistent with insider shareholding disclosures rather than a report or announcement of a report.
2024-09-09 Chinese
113年08月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, supervisors, and senior management, showing their current holdings, pledged shares, and related percentages. It lists individual names, titles, and share counts, focusing on insider share ownership and pledges. There is no indication of financial results, earnings, management discussion, or regulatory certifications. The content matches the description of a Director's Dealing report, which reports personal share transactions or holdings by company directors and executives. The document length is 3188 characters, which is consistent with a detailed insider shareholding disclosure rather than a brief announcement or a full financial report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2024-09-09 Chinese
本公司接獲新藥Nephoxil韓國授權夥伴韓國協和麒麟公司 「Kyowa Kirin Korea Co., Ltd.」(以下簡稱為KKKR) 因其母 公司對亞太地區業務重組，故通知終止授權與獨家經銷合約
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (1760 寶齡富錦) regarding the termination of a licensing and exclusive distribution agreement with its Korean partner Kyowa Kirin Korea Co., Ltd. It details the contract termination date, reasons, and impact on the company. The document is short (1291 characters) and serves as a factual disclosure of a material event affecting shareholder interests and company operations. It does not contain financial statements, detailed financial analysis, or comprehensive report content. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or presentation. It is a regulatory announcement about a material contract termination event, fitting best under Regulatory Filings (RNS).
2024-08-27 Chinese
113年第2季海外子公司投資
Regulatory Filings Classification · 90% confidence The document is a financial disclosure from a publicly listed company, 宝齡富錦, showing detailed investment information in overseas subsidiaries for the second quarter of the 113th year (likely referring to a fiscal quarter). It includes investment amounts, shareholding percentages, and recognized investment gains or losses. The document is relatively short (1241 characters) and contains specific financial data related to investments, but it does not present a full financial report or comprehensive financial statements. It appears to be a regulatory disclosure of investment holdings and results rather than a full annual or interim report. Given the nature of the data and the context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific report types.
2024-08-13 Chinese
113年第2季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investments in mainland China by a Taiwanese listed company, including investment amounts, methods, and related notes. It contains financial figures and regulatory references to the Ministry of Economic Affairs Investment Commission limits. The document length is 1925 characters, which is relatively short and appears to be a regulatory disclosure rather than a full financial report. It does not contain comprehensive financial statements or management discussion but rather specific investment data and compliance information. This type of document fits best under Regulatory Filings (RNS), as it is a regulatory disclosure about investment activities and compliance, not a full annual or interim report or other specific report types.
2024-08-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.